Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Zikani Therapeutics

Request full access

Ribosome modulating agents for rare genetic diseases

Watertown, United StatesFounded 2015Biotech & Life Sciences

About Zikani Therapeutics

Zikani Therapeutics, founded in 2015 and based in Watertown, Massachusetts, was a clinical-stage biopharmaceutical company focused on developing therapies for rare diseases and oncology. The company's core technology was its TURBO-ZM™ platform, a synthetic chemistry platform used to design and develop orally delivered, macrolide-based Ribosome Modulating Agents (RMAs). These RMAs were engineered to modulate the function of the ribosome, the cellular machinery that creates proteins, in a disease-specific manner.

The primary application of Zikani's technology was to address diseases caused by nonsense mutations. These genetic mutations introduce a premature stop signal during protein synthesis, resulting in non-functional proteins. Zikani's RMAs were designed to enable the ribosome to read through these erroneous stop signals, thereby restoring the production of full-length, functional proteins. The company showed promising pre-clinical data in several areas, including cystic fibrosis, familial adenomatous polyposis (FAP), recessive dystrophic epidermolysis bullosa (RDEB), and junctional epidermolysis bullosa (JEB).

In April 2021, Zikani Therapeutics was acquired by Eloxx Pharmaceuticals in an all-stock transaction. The acquisition was intended to combine Zikani's TURBO-ZM™ platform and preclinical pipeline with Eloxx's lead candidate, ELX-02, creating a more robust entity focused on ribosomal RNA-targeted therapies. As part of the acquisition, Zikani's leadership team transitioned to Eloxx, with Sumit Aggarwal becoming the President and CEO, and Vijay Modur, M.D., Ph.D., being appointed Head of Research and Development of the combined company. Prior to the acquisition, Zikani had raised $61.7M in funding over several rounds from investors including Gurnet Point Capital, Advent Life Sciences, and Roche Venture Fund.

Source: Dealroom company data

At a glance

Founded
2015
Headquarters
Watertown, United States
Sector
Biotech & Life Sciences

Zikani Therapeutics in the Watertown ecosystem

Live from Dealroom

The Zikani Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • CARB-X

Series A5 investors entered at this stage

  • Novartis Venture Fund
  • SR One
  • Gurnet Point Capital
  • Roche Venture Fund
  • Advent Life Sciences
Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Watertown HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Zikani Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Zikani Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.